respiratory
Lung cancer

Disappointing results for mesothelioma trial


Data from the highly anticipated PROMISE-meso trial failed to deliver, with no PFS or OS benefit seen for pembrolizumab compared to standard chemotherapy. The Phase III trial, presented at the European Society for Medical Oncology Congress 2019 in Barcelona, involved 144 patients with advanced pre-treated mesothelioma who were randomised to pembrolizumab (200 mg every three ...

Already a member?

Login to keep reading.


OR
© 2019 the limbic